The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue , 2013, Pages S29-S32

  Ruderman, Eric M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HUMAN; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888348574     PISSN: 23284633     EISSN: 23285273     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552-63.
2. Matsuno H, Yoshida K, Ochiai A, Okamoto M. Requirement of methotrexate in combination with anti-tumor necrosis factoralpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis. J Rheumatol. 2007 Dec;34(12):2326-33. Epub 2007 Nov 15.
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007 Jul;66(7):921-6. Epub 2007 Feb 14.
4. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26-37.
5. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9.
6. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81.
7. Kameda H, Kanbe K, Sato E, et al. Continuation of metho trexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011 Aug;38(8):1585-92. doi: 10.3899/jrheum.110014. Epub 2011 May 15.
8. Kameda H, Ueki Y, Saito K, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010 Dec;20(6):531-8. doi: 10.1007/s10165-010-0324-4. Epub 2010 Jun 24.
9. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun;350(25):2572-81.
10. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an openlabel, clinical practice study. Arthritis Care Res (Hoboken). 2013 Mar;65(3):362-71. doi: 10.1002/acr.21847.
11. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43-50. doi: 10.1136/annrheumdis-2011-201282. Epub 2012 May 5.
12. Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another diseasemodifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 Jun;54(6):1786-94.
13. Kristensen LE, Kapetanovic MC, Gülfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008 Apr;47(4):495-9. doi: 10.1093/rheumatology/ken002. Epub 2008 Mar 3.
14. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8(6):R174.
15. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.
16. Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1.
17. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011 Jul;33(7):901-13. doi: 10.1016/j.clinthera.2011.06.001. Epub 2011 Jun 29.
18. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013 Sep;32(9):1347-55. doi: 10.1007/s10067-013-2281-8. Epub 2013 May 24